PAVmed Inc. (PAVM): Price and Financial Metrics
GET POWR RATINGS... FREE!
PAVM Stock Price Chart Interactive Chart >
PAVM Price/Volume Stats
|Current price||$9.39||52-week high||$9.70|
|Prev. close||$8.21||52-week low||$1.63|
|Day high||$9.70||Avg. volume||3,080,070|
|50-day MA||$7.05||Dividend yield||N/A|
|200-day MA||$4.86||Market Cap||795.97M|
PAVmed Inc. (PAVM) Company Bio
PAVmed Inc. operates as a medical device company in the United States. Its product pipeline includes PortIO, a long-term implantable vascular access device; CarpX, a percutaneous device to treat carpal tunnel syndrome; NextCath, a self-anchoring catheter; DisappEAR: Antibiotic-eluting resorbable ear tube; NextFlo, a disposable infusion pump; and Caldus, a disposable tissue ablation device. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was founded in 2014 and is based in New York, New York.
Most Popular Stories View All
PAVM Latest News Stream
|Loading, please wait...|
PAVM Latest Social Stream
View Full PAVM Social Stream
Latest PAVM News From Around the Web
Below are the latest news stories about PAVmed Inc that investors may wish to consider to help them evaluate PAVM as an investment opportunity.
PAVmed Subsidiary Veris Health Joins Microsoft for Startups Global Program and Engages Loka as Software Development Partner
NEW YORK--(BUSINESS WIRE)---- $pavm--PAVmed subsidiary Veris Health joins Microsoft for startups global program and engages Loka as software development partner.
The Daily Biotech Pulse: MacroGenics'' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA''s FDA Nod
Here''s a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 7) Adial Pharmaceuticals, Inc. (NASDAQ: ADIL ) Axonics, Inc. (NASDAQ: AXNX ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Candel Therapeutics, Inc. (NASDAQ: CADL ) (announced completion of patient enrollment in the pivotal phase 3 study of CAN-2409 in prostate cancer) Cardiol Therapeutics Inc. (NASDAQ: CRDL ) (announced addition to its board) Caribou Biosciences, Inc. (NASDAQ: CRBU ) Catalent, Inc. (NASDAQ: CTLT ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE ) Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX ) Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN ) Edwards Lifesciences Corporation (NYSE: EW ) Er...
NEW YORK, September 07, 2021--PAVmed to participate in September investor and MedTech conferences.
Investors are growing impatient about a planned spinoff.
NEW YORK--(BUSINESS WIRE)---- $pavm--PAVmed Provides Business Update and Preliminary Second Quarter 2021 Financial Results. Conference call to be held today at 4:30 PM EDT.
PAVM Price Returns